相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease
Salvatore Spina et al.
BRAIN (2021)
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research
Christina M. Moloney et al.
ALZHEIMERS & DEMENTIA (2021)
Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease
Elisabeth H. Thijssen et al.
SCIENTIFIC REPORTS (2021)
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Stephen Salloway et al.
NATURE MEDICINE (2021)
The development and convergence of co-pathologies in Alzheimer's disease
John L. Robinson et al.
BRAIN (2021)
Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome A Randomized Clinical Trial
Richard M. Tsai et al.
JAMA NEUROLOGY (2020)
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease
Tosha Williams et al.
MOLECULAR NEURODEGENERATION (2020)
Another step forward in blood-based diagnostics for Alzheimer's disease
Randall J. Bateman et al.
NATURE MEDICINE (2020)
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Shorena Janelidze et al.
NATURE MEDICINE (2020)
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
Elisabeth H. Thijssen et al.
NATURE MEDICINE (2020)
Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study
Eric M. Reiman et al.
NATURE COMMUNICATIONS (2020)
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Shorena Janelidze et al.
NATURE COMMUNICATIONS (2020)
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification
Nicolas R. Barthelemy et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling data from four cohorts
Thomas K. Karikari et al.
LANCET NEUROLOGY (2020)
A beta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease
Niklas Mattsson-Carlgren et al.
SCIENCE ADVANCES (2020)
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease
Nicolas R. Barthelemy et al.
NATURE MEDICINE (2020)
World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia
Miia Kivipelto et al.
ALZHEIMERS & DEMENTIA (2020)
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
Sebastian Palmqvist et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Gill Livingston et al.
LANCET (2020)
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease
Tiantian Guo et al.
MOLECULAR NEURODEGENERATION (2020)
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease
Simon Dujardin et al.
NATURE MEDICINE (2020)
Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration
Maud Gratuze et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Panel discussion: DIAN‐TU trial collaborative effort
Randall J. Bateman et al.
Alzheimers & Dementia (2020)
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis
Steffi De Meyer et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Advancing combination therapy for Alzheimer's disease
Stephen P. Salloway et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2020)
ApoE4: an emerging therapeutic target for Alzheimer's disease
Mirna Safieh et al.
BMC MEDICINE (2019)
Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial
Orestes V. Forlenza et al.
BRITISH JOURNAL OF PSYCHIATRY (2019)
Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease
David Henley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease
Michael F. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer's Disease
Nicolas R. Barthelemy et al.
FRONTIERS IN AGING NEUROSCIENCE (2019)
α-synuclein in the pathophysiology of Alzheimer's disease
Daniel Twohig et al.
MOLECULAR NEURODEGENERATION (2019)
TREM2 function impedes tau seeding in neuritic plaques
Cheryl E. G. Leyns et al.
NATURE NEUROSCIENCE (2019)
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Suzanne E. Schindler et al.
NEUROLOGY (2019)
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau
Matthias Brendel et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report
Joseph F. Arboleda-Velasquez et al.
NATURE MEDICINE (2019)
Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options
Jeffrey L. Cummings et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology
Hongjun Fu et al.
NATURE NEUROSCIENCE (2019)
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Suzanne E. Schindler et al.
ALZHEIMERS & DEMENTIA (2019)
Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force
S. Gauthier et al.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2019)
Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics
Elizabeth E. Blue et al.
ALZHEIMERS & DEMENTIA (2019)
Alzheimer's disease drug development pipeline: 2019
Jeffrey Cummings et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
An Overview on the Clinical Development of Tau-Based Therapeutics
Miguel Medina
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
The Neurotoxic Role of Extracellular Tau Protein
Alvaro Sebastian-Serrano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease
Michael F. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Lawrence S. Honig et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial
Ana-Maria Lacosta et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
BACE inhibitors in clinical development for the treatment of Alzheimer's disease
Francesco Panza et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2018)
New insights into the role of TREM2 in Alzheimer's disease
Maud Gratuze et al.
MOLECULAR NEURODEGENERATION (2018)
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study
Philip Scheltens et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
Advances in spinal muscular atrophy therapeutics
Valeria Parente et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Yang Shi et al.
NATURE (2017)
Cryo-EM structures of tau filaments from Alzheimer's disease
Anthony W. P. Fitzpatrick et al.
NATURE (2017)
Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease
Sylvia E. Perez et al.
NEUROBIOLOGY OF AGING (2017)
Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases
Kathleen M. Schoch et al.
NEURON (2017)
Elucidating the Role of TREM2 in Alzheimer's Disease
Jason D. Ulrich et al.
NEURON (2017)
TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy
Cheryl E. G. Leyns et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
Sarah L. DeVos et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
TREM2, Microglia, and Neurodegenerative Diseases
Felix L. Yeh et al.
TRENDS IN MOLECULAR MEDICINE (2017)
The Effects of NOS2 Gene Deletion on Mice Expressing Mutated Human AβPP
Carol A. Colton et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Vitaliy Ovod et al.
ALZHEIMERS & DEMENTIA (2017)
Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition
Juliane Schelle et al.
ALZHEIMERS & DEMENTIA (2017)
Age-related macular degeneration: genome-wide association studies to translation
James R. M. Black et al.
GENETICS IN MEDICINE (2016)
Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease
Matthew R. Halliday et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2016)
Tau in physiology and pathology
Yipeng Wang et al.
NATURE REVIEWS NEUROSCIENCE (2016)
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease
Rik Ossenkoppele et al.
BRAIN (2016)
Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence
Yu Yamazaki et al.
CNS DRUGS (2016)
The amyloid hypothesis of Alzheimer's disease at 25years
Dennis J. Selkoe et al.
EMBO MOLECULAR MEDICINE (2016)
Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease
Florence Pasquier et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Yaming Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies
Todd E. Golde
JOURNAL OF NEUROCHEMISTRY (2016)
The amyloid cascade hypothesis: are we poised for success or failure?
Eric Karran et al.
JOURNAL OF NEUROCHEMISTRY (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer's mice
Arne Ittner et al.
SCIENCE (2016)
BACE1 Physiolocical Functions May Limit Its Use as Therapeutic Tarcet for Alzneimer's Disease
Soraia Barao et al.
TRENDS IN NEUROSCIENCES (2016)
Drug development in Alzheimer's disease: the path to 2025
Jeffrey Cummings et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies
Jens Wagner et al.
ACTA NEUROPATHOLOGICA (2015)
Age and amyloid effects on human central nervous system amyloid-beta kinetics
Bruce W. Patterson et al.
ANNALS OF NEUROLOGY (2015)
The Platform Trial An Efficient Strategy for Evaluating Multiple Treatments
Scott M. Berry et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial
Tiia Ngandu et al.
LANCET (2015)
Genetics ignite focus on microglial inflammation in Alzheimer's disease
Manasi Malik et al.
MOLECULAR NEURODEGENERATION (2015)
Monitoring of chronic γ-secretase modulator treatment by serial amyloid-PET
M Brendel et al.
MOLECULAR PSYCHIATRY (2015)
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease
Rachelle S. Doody et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease
Martin R. Farlow et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Tau aggregation and its interplay with amyloid-β
Rebecca M. Nisbet et al.
ACTA NEUROPATHOLOGICA (2015)
APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba
Hugh C. Hendrie et al.
INTERNATIONAL PSYCHOGERIATRICS (2014)
Harmonized diagnostic criteria for Alzheimer's disease: recommendations
J. C. Morris et al.
JOURNAL OF INTERNAL MEDICINE (2014)
Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer's disease
Verena Landel et al.
MOLECULAR NEURODEGENERATION (2014)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease
Evan Dorey et al.
NEUROSCIENCE BULLETIN (2014)
Alzheimer's disease drug-development pipeline: few candidates, frequent failures
Jeffrey L. Cummings et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy
Jeffrey M. Keil et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2014)
Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) The Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group
John Breitner et al.
ALZHEIMERS & DEMENTIA (2013)
Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation
Alex Crowe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
APOE-ε2 and APOE-ε4 Correlate With Increased Amyloid Accumulation in Cerebral Vasculature
Peter T. Nelson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2013)
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Stephanie J. B. Vos et al.
LANCET NEUROLOGY (2013)
Tau pathology and neurodegeneration
Maria Grazia Spillantini et al.
LANCET NEUROLOGY (2013)
APOE genotype and MRI markers of cerebrovascular disease Systematic review and meta-analysis
Sabrina Schilling et al.
NEUROLOGY (2013)
Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein
Luis F. Maia et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Rachel Potter et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Safety and biomarker effects of Solanezumab in patients with Alzheimer's disease
Martin Farlow et al.
ALZHEIMERS & DEMENTIA (2012)
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Bradley T. Hyman et al.
ALZHEIMERS & DEMENTIA (2012)
Mouse Models of Frontotemporal Dementia
Erik D. Roberson
ANNALS OF NEUROLOGY (2012)
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
Peter T. Nelson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)
The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice
Bin Zhang et al.
JOURNAL OF NEUROSCIENCE (2012)
Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide
Tadafumi Hashimoto et al.
JOURNAL OF NEUROSCIENCE (2012)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
Randall J. Bateman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
Lucy E. Farrimond et al.
BMJ OPEN (2012)
The role of inflammatory processes in Alzheimer’s disease
G. Joseph Broussard et al.
INFLAMMOPHARMACOLOGY (2012)
Extended results of the Alzheimer's disease anti-inflammatory prevention trial
John C. Breitner et al.
ALZHEIMERS & DEMENTIA (2011)
The projected effect of risk factor reduction on Alzheimer's disease prevalence
Deborah E. Barnes et al.
LANCET NEUROLOGY (2011)
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
Eric Karran et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
Randall J. Bateman et al.
ALZHEIMERS RESEARCH & THERAPY (2011)
Accumulation of intraneuronal Aβ correlates with ApoE4 genotype
Ditte Z. Christensen et al.
ACTA NEUROPATHOLOGICA (2010)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack et al.
LANCET NEUROLOGY (2010)
Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results
Curtis L. Meinert et al.
ALZHEIMERS & DEMENTIA (2009)
APOE genotype-specific differences in the innate immune response
Michael P. Vitek et al.
NEUROBIOLOGY OF AGING (2009)
The amyloid cascade hypothesis
Amos D. Korczyn
ALZHEIMERS & DEMENTIA (2008)
A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics
Hanna Rosenmann et al.
EXPERIMENTAL NEUROLOGY (2008)
No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial
Danielle de Jong et al.
PLOS ONE (2008)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Microglia and Alzheimer's disease pathogenesis
WJ Streit
JOURNAL OF NEUROSCIENCE RESEARCH (2004)
Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase - Modulation by zinc
FM Harris et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Triple-transgenic model of Alzheimer's disease with plaques and tangles:: Intracellular Aβ and synaptic dysfunction
S Oddo et al.
NEURON (2003)
APOE ε4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein
K Chalmers et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2003)
Genetic and environmental risk factors for intracerebral Hemorrhage - Preliminary results of a population-based study
D Woo et al.
STROKE (2002)
Randomized pilot study of nimesulide treatment in Alzheimer's disease
PS Aisen et al.
NEUROLOGY (2002)
The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice
J Wegiel et al.
NEUROBIOLOGY OF AGING (2001)
分享论文
